




EMORY

ROLLINS  
SCHOOL OF  
PUBLIC  
HEALTH

# Defining Vaccine Effects

Session 6a



R. RANNEY ROLLINS BUILDING

# Outline

## 1. Mechanisms of vaccine protection

### a. Against

- Infection
- Disease
- Infectiousness

### b. Leaky or all-or-nothing

## 2. Types of vaccine effects



# Vaccine efficacy measures...

Typically VE refers to “**Vaccine Efficacy for Susceptibility**”

- Against infection ( $VE_s$ )
- Against disease ( $VE_d$ )

“**Vaccine Efficacy for Infectiousness**” ( $VE_i$ )

- The per-contact transmission probability **FROM** infected vaccinated people compared to infected un-vaccinated people



$VE_s$  : protection against infection

$VE_d$  : protection against disease

$VE_i$  : protection against infectiousness



# Protection against infection or disease?

	Inactivated Polio Vaccine (IPV)	Oral Polio Vaccine (OPV)
Developed	1955 by Jonas Salk	1950s by Albert Sabin
Formulation	Killed, injectable	Live, oral
Serotypes	3 serotypes	1,2 or 3 serotype
Protective immunity	Excellent	Excellent
Mucosal immunity	Little -> wild virus can still multiply in the intestines and be shed in the feces, risking continued circulation	Excellent -> so effective at interrupting transmission of the virus




The  
mainstay of  
global  
eradication

# Mechanisms of vaccination

## Leaky immune protection


Also known as degree-type or partial protection  
partially reduce susceptibility to  
infection for all vaccinated individuals



No correlate of protection

## All-or-nothing immune protection

Also known as take-type  
confer complete protection to the  
fraction of people who respond to  
vaccines



There may be a correlate of protection

50% VE

# Types of vaccine effect measures

## Direct effect

- The biological protection of the vaccine
- Relative risk of vaccinated individual compared to unvaccinated

## Indirect effect

- The degree of protection that unvaccinated individuals receive in the presence versus the absence of a vaccine program,
- at a given level of coverage


## Total effect

- Relative risk of vaccinated individuals in vaccinated population to unvaccinated individuals in unvaccinated population,
- at a given level of coverage

## Overall effect

- Relative risk of average individual in a population with a vaccination program to an average individual in a comparable population with no vaccination,
- at a given level of coverage


# Evaluation of Vaccine Effects






# Direct effectiveness

- Biological protection of a vaccine




# Indirect effectiveness

- “Herd protection”
- Protection that unvaccinated individuals receive in the presences versus absence of a vaccination program




# Total effectiveness

- The combination of biologic and indirect protection received by vaccinated individuals




# Overall effectiveness

- “Vaccine impact”
- Public health benefit of a vaccination program, weighting total effects among vaccinated and indirect effects among unvaccinated populations




# Intervention effects



# Intervention effects -- Notation

- Do not receive intervention
- Receive intervention





# Calculation of effects


$$VE_{direct} = \left(1 - \frac{I_{11}}{I_{10}}\right) * 100\%$$

$$VE_{indirect} = \left(1 - \frac{I_{10}}{I_0}\right) * 100\%$$

$$VE_{overall} = \left(1 - \frac{I_1}{I_0}\right) * 100\%$$

$$VE_{total} = \left(1 - \frac{I_{11}}{I_0}\right) * 100\%$$

# Which vaccine effects depend on coverage?



# Effects of the rotavirus vaccine program across age groups in the United States: analysis of national claims data, 2001–2016



Julia M. Baker<sup>1,2\*</sup> , Rebecca M. Dahl<sup>3</sup>, Justin Cubilo<sup>1</sup>, Umesh D. Parashar<sup>2</sup> and Benjamin A. Lopman<sup>1,2</sup>

**Table 1** Vaccine effectiveness against RVGE hospitalization during the post-vaccine period by age group

Age Group	Direct VE, % (95% CI)	Indirect VE, % (95% CI)	Overall VE, % (95% CI)	Total VE, % (95% CI)
< 1	80* (70, 87)	79* (66, 87)	88* (82, 92)	96* (93, 97)
1	92* (87, 95)	59* (33, 76)	79* (65, 88)	97* (95, 98)
2	87* (76, 93)	43* (4, 67)	68* (44, 83)	93* (86, 96)
3	96* (89, 99)	42 (− 2, 68)	71* (47, 84)	97* (93, 99)
4	81* (53, 93)	36 (− 25, 68)	59* (22, 79)	88* (70, 96)
0–4	87* (83, 90)	60* (48, 69)	78* (71, 83)	95* (93, 96)
5–9	47 (− 12, 79)	48* (30, 61)	50* (34, 63)	72* (42, 89)
10–14		46* (14, 67)	Equivalent to indirect VE <sup>a</sup>	
15–24		42* (10, 62)		
25–44		56* (36, 70)		
45–64		35* (9, 53)		
All ages			69* (62, 76)	

\*Represents significance at the alpha = 0.05 level

<sup>a</sup>Indirect and overall VE are equivalent for children, adolescents, and adults over 9 years of age because there are no vaccinated individuals in these age groups

# Summary

Vaccines may act against infection, disease or infectiousness

Two concepts of vaccine action

- All-or-nothing
- Leaky

Types of vaccine effects – the latter 3 depend on coverage

- Direct
- Indirect
- Total
- Overall